» Articles » PMID: 37451849

Prediction of Worsening Heart Failure in Hypertrophic Cardiomyopathy Using Plasma Proteomics

Overview
Journal Heart
Date 2023 Jul 14
PMID 37451849
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Heart failure (HF) is one of the most common and lifestyle-limiting complications of hypertrophic cardiomyopathy (HCM). Prediction of worsening HF using clinical measures alone remains limited. Moreover, the mechanisms by which patients with HCM develop worsening HF have not been elucidated. Therefore, the aim of this study was to develop a plasma proteomics-based model to predict worsening HF among patients with HCM and to identify signalling pathways that are differentially regulated in those who subsequently develop worsening HF.

Methods: In this multi-centre, prospective cohort study of 389 patients with HCM, plasma proteomics profiling of 4986 proteins was performed at enrolment. A proteomics-based random forest model was developed to predict worsening HF using data from one institution (training set, n=268). This model was externally validated in patients from a different institution (test set, n=121). Pathway analysis of proteins significantly dysregulated in patients who subsequently developed worsening HF compared with those who did not was executed, using a false discovery rate (FDR) threshold of <0.001.

Results: Using the 11-protein proteomics-based model derived from the training set, the area under the receiver-operating characteristic curve to predict worsening HF was 0.87 (95% CI: 0.76 to 0.98) in the test set. Pathway analysis revealed that the Ras-MAPK pathway (FDR<0.00001) and related pathways were dysregulated in patients who subsequently developed worsening HF.

Conclusions: The present study with comprehensive plasma proteomics profiling demonstrated a high accuracy to predict worsening HF in patients with HCM and identified the Ras-MAPK and related signalling pathways as potential underlying mechanisms.

Citing Articles

The Role of Signalling Pathways in Myocardial Fibrosis in Hypertrophic Cardiomyopathy.

Skorka P, Piotrowski J, Bakinowska E, Kielbowski K, Pawlik A Rev Cardiovasc Med. 2025; 26(2):27152.

PMID: 40026508 PMC: 11868901. DOI: 10.31083/RCM27152.


Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP.

Osawa I, Akita K, Hasegawa K, Fifer M, Tower-Rader A, Reilly M Circ Heart Fail. 2025; 18(2):e012343.

PMID: 39831317 PMC: 11835532. DOI: 10.1161/CIRCHEARTFAILURE.124.012343.


Potential of plasma biomarkers for heart failure prediction, management, and prognosis: A multiomics perspective.

Zou E, Xu X, Chen L Heart Fail Rev. 2024; 30(1):55-67.

PMID: 39377997 DOI: 10.1007/s10741-024-10443-5.


Comprehensive Proteomic Profiling of Human Myocardium Reveals Signaling Pathways Dysregulated in Hypertrophic Cardiomyopathy.

Lumish H, Sherrid M, Janssen P, Ferrari G, Hasegawa K, Castillero E J Am Coll Cardiol. 2024; 84(20):1999-2011.

PMID: 39365226 PMC: 11817648. DOI: 10.1016/j.jacc.2024.07.043.


Investigation of coagulation and proteomics profiles in symptomatic feline hypertrophic cardiomyopathy and healthy control cats.

Jiwaganont P, Roytrakul S, Thaisakun S, Sukumolanan P, Petchdee S BMC Vet Res. 2024; 20(1):292.

PMID: 38970022 PMC: 11225243. DOI: 10.1186/s12917-024-04170-0.

References
1.
Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F . Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res. 1998; 83(6):594-601. DOI: 10.1161/01.res.83.6.594. View

2.
Ommen S, Mital S, Burke M, Day S, Deswal A, Elliott P . 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142(25):e558-e631. DOI: 10.1161/CIR.0000000000000937. View

3.
Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A . False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005; 21(13):3017-24. DOI: 10.1093/bioinformatics/bti448. View

4.
Saberi S, Cardim N, Yamani M, Schulz-Menger J, Li W, Florea V . Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. Circulation. 2020; 143(6):606-608. DOI: 10.1161/CIRCULATIONAHA.120.052359. View

5.
Shimada Y, Hasegawa K, Kochav S, Mohajer P, Jung J, Maurer M . Application of Proteomics Profiling for Biomarker Discovery in Hypertrophic Cardiomyopathy. J Cardiovasc Transl Res. 2019; 12(6):569-579. PMC: 7102897. DOI: 10.1007/s12265-019-09896-z. View